Exubrion elevates Gregory Taglialatela to chief commercial officer
Bottom line
Exubrion Therapeutics has promoted Gregory Taglialatela to chief commercial officer, effective July 1, 2026, elevating a longtime commercial leader as the company looks to expand access to Synovetin OA, its injectable treatment for canine osteoarthritis. In the role, Taglialatela will oversee national sales, key account management, business development, and broader growth initiatives in the U.S. and internationally. Exubrion said he joined the company in 2022 and most recently served as national account director. (exubrion.com)
Why it matters: For veterinary professionals, this is a commercial leadership move tied directly to how quickly Synovetin OA reaches more treatment centers and referral networks. Synovetin OA is positioned as a localized, intra-articular treatment that targets synovial inflammation and can provide up to a year of pain relief from a single treatment, which makes commercial execution, training, and treatment-center support especially important for practices evaluating where it fits alongside NSAIDs and anti-NGF options. Published company-supported research in dogs with grade 3 elbow osteoarthritis reported pain and lameness improvement for up to one year after a single injection, while FDA materials and Exubrion’s own positioning underscore that the broader canine OA market remains active and competitive. (exubrion.com)
What to watch: Watch for whether Exubrion uses this leadership change to accelerate treatment-center expansion, international growth, and new clinical or real-world data around Synovetin OA. (exubrion.com)
Exubrion Therapeutics has promoted Gregory Taglialatela to chief commercial officer, effective July 1, 2026, in a move that signals the company is sharpening its commercial push behind Synovetin OA, its canine osteoarthritis product. The announcement, published July 22, said Taglialatela will now lead commercial strategy and execution across sales, key accounts, business development, and strategic growth initiatives. (exubrion.com)
The promotion comes at a notable point for Exubrion. The company has spent the past several years building awareness of Synovetin OA as a differentiated osteoarthritis option for dogs, centered on radiosynoviorthesis using tin-117m. Exubrion describes the treatment as a localized injection intended to reduce synovial inflammation within the affected joint, and says the product can provide up to one year of pain relief after a single treatment. Its public-facing materials also show an ongoing effort to grow both veterinarian education and treatment-center access. (exubrion.com)
Taglialatela’s background helps explain the choice. Exubrion said he has more than 15 years of animal health experience and has held several roles since joining the company in 2022, including sales manager, regional business development manager, and national account director. Executive chair Laurie McRay said his leadership and industry relationships make him the right person to lead the company’s next growth phase, while Taglialatela said he plans to work with customers and treatment-center partners to expand access to the therapy. (exubrion.com)
The commercial stakes are significant because Synovetin OA is not a typical shelf product. It requires trained administration in veterinary settings and sits in a fast-evolving canine OA landscape. In a 2021 PLOS One study of 14 client-owned dogs with grade 3 elbow osteoarthritis, investigators reported that a single intra-articular tin-117m colloid treatment was associated with significant reductions in pain and lameness and improved functionality for up to a year, with no adverse treatment-related effects reported in that study. Exubrion has continued to point to additional supporting literature, including a 2025 review on disease-modifying potential and a 2026 JAVMA narrative review listed on its site. (journals.plos.org)
Industry context also matters here. Canine OA remains one of the most common chronic conditions seen in practice, and veterinarians are weighing multiple treatment pathways, including NSAIDs, rehabilitation, joint-directed therapies, and anti-NGF monoclonal antibodies. FDA’s recent communication on adverse event reports associated with Librela has kept attention on safety monitoring and treatment selection in this category, even as the agency reiterated that post-market surveillance can surface events not seen before approval. That doesn’t make Synovetin OA a direct substitute in every case, but it does reinforce why commercial positioning, case selection, and clinician education are becoming more important across the OA market. (fda.gov)
Why it matters: For veterinary professionals, this promotion is less about a title change than about execution. If Exubrion expands treatment-center capacity, strengthens account support, and improves practice onboarding, more clinics may take a closer look at whether Synovetin OA fits into multimodal OA protocols, especially for dogs that need longer-duration relief or for pet parents looking to reduce the burden of frequent systemic medication. At the same time, veterinarians will still need to weigh evidence quality, workflow demands, radiation-handling considerations, case eligibility, cost, and how the therapy compares with more familiar OA tools. (exubrion.com)
Expert reaction beyond the company’s own announcement was limited in publicly available coverage at the time of reporting, but Exubrion’s messaging has been consistent: the company is framing Synovetin OA not only as a pain-control option, but as a therapy aimed at the inflammatory process inside the joint. That positioning could resonate with practices looking for alternatives to purely symptom-focused management, though broader independent commentary and real-world comparative data would make the picture clearer. This is an inference based on Exubrion’s recent educational and data-sharing efforts, rather than a statement the company made directly. (exubrion.com)
What to watch: The next signals will be practical ones, including whether Exubrion announces more treatment centers, international expansion, new partnerships, or additional peer-reviewed and real-world outcomes data that help veterinarians judge where Synovetin OA belongs in long-term canine OA care. (exubrion.com)